Portal de investigación
- Inicio
- Proyectos y Estudios
- ENSAYO FASE III MULTICÉNTRICO, RANDOMIZADO COMPARANDO 6 CICLOS DE RÉGIMEN FAC (FLUOROURACILO, DOXORRUBICINA, Y CICLOFOSFAMIDA) CON 4 CICLOS DE RÉGIMEN FAC SEGUIDO DE 8 ADMINISTRACIONES DE TAXOL SEMANAL EN RÉGIMEN SECUENCIAL, COMO TRATAMIENTO ADYUVANTE DE PACIENTES CON CÁNCER DE MAMA OPERADO Y SIN AFECTACIÓN AXILAR.
ENSAYO FASE III MULTICÉNTRICO, RANDOMIZADO COMPARANDO 6 CICLOS DE RÉGIMEN FAC (FLUOROURACILO, DOXORRUBICINA, Y CICLOFOSFAMIDA) CON 4 CICLOS DE RÉGIMEN FAC SEGUIDO DE 8 ADMINISTRACIONES DE TAXOL SEMANAL EN RÉGIMEN SECUENCIAL, COMO TRATAMIENTO ADYUVANTE DE PACIENTES CON CÁNCER DE MAMA OPERADO Y SIN AFECTACIÓN AXILAR.
Datos básicos
- Código:
- GEICAM/2003-02
- Protocolo:
- GEICAM/2003-02
- EUDRACT:
- 2005-003109-10
- NCT:
- Centro:
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
2017 SEOM guidelines: a multidisciplinary approach
Santaballa, A, Vera, R
Editorial Material. 10.1007/s12094-018-1830-7. 2018
A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
de la Fuente, Ana; (...); Ravassa, Susana
Article. 10.3390/cancers14122941. 2022
A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trial-A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.
Perez-Fidalgo, JA; (...); Gonzalez-Martin, A
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.TPS5610. 2018
A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit to prior P-based treatment (BIOPER)
Llombart-Cussac, A; (...); Albanell, J
Meeting Abstract. 2021
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
Gavilá J; (...); Llombart-Cussac A
Article. 10.1007/s12094-019-02145-4. 2020
A Smart Digital Health Platform to Enable Monitoring of Quality of Life and Frailty in Older Patients with Cancer: A Mixed-Methods, Feasibility Study Protocol.
Papachristou, Nikolaos; (...); Bamidis, Panagiotis D.
Article. 10.1016/j.soncn.2023.151437. 2023
Adherence and adverse events of intraperitoneal chemotherapy in optimally debulked ovarian cancer patients: Real-life study.
Ballesta-López O; (...); Poveda-Andrés JL
Article. 10.1177/1078155220915953. 2020
ANALYSIS OF THE CLINICAL EXPERIENCE WITHIN RUCAPARIB'S EARLY ACCESS PROGRAM IN SPAIN - A GEICO STUDY
Yubero-Esteban, A.; (...); Gonzalez-Martin, A.
Meeting Abstract. 10.1136/ijgc-2021-ESGO.398. 2021
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).
Tavira B; (...); González-Martín A
Article. 10.1158/1078-0432.CCR-23-0771. 2024
Anthracycline mediated cardiotoxicity: Detection of miRNA based early biomarkers for the prediction of myocardial injury. Hecatos study
Coloma, C. Salvador; (...); Santaballa, A.
Meeting Abstract. 10.1093/annonc/mdw365.69. 2016
Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial
Martin, A. Gonzalez; (...); Selle, F.
Meeting Abstract. 10.1016/j.annonc.2023.10.031. 2023
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.
Gonzalez-Martin, Antonio; (...); Selle, Frederic
Article. 10.1200/JCO.24.00668. 2024
Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations.
López-Fernández T; (...); López Sendón Henchel JL
Article. 10.1016/j.rec.2016.12.041. 2017
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
Perez-Fidalgo, Jose Alejandro; (...); Gonzalez-Martin, Antonio
Article. 10.1136/ijgc-2022-004028. 2023
Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO.
Yubero-Esteban, Alfonso; (...); Sanchez Lorenzo, Maria Luisa
Meeting Abstract. 2022
Clinical insights from the rucaparib access program in Spain: A sub-analysis of long-term responders by GEICO.
Yubero-Esteban, Alfonso; (...); Gonzalez Martin, Antonio
Meeting Abstract. 2022
Current Status of Cardio-Oncology in Spain: A National Multidisciplinary Survey.
Martín-García A; (...); López-Fernández T
Letter. 10.1016/j.rec.2017.11.002. 2019
Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2-metastatic breast cancer from the GEICAM/2013-02 PEARL study
Guerrero, Angel; (...); Martin, Miguel
Meeting Abstract. 2023
Characterization of the gene expression profile of breast cancer tumours in patients undergoing ovarian stimulation for fertility preservation purposes
Soriano, M. J.; (...); Diaz-Garcia, C.
Meeting Abstract. 2022
Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients
Salvador-Coloma, C; (...); Santaballa, A
Meeting Abstract. 2018
Effectiveness of group therapy in women with localized breast cancer
Bellver-Perez, A, Peris-Juan, C, Santaballa-Beltran, A
Article. 10.1016/j.ijchp.2019.02.001. 2019
Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)
Rubio, MJ; (...); Santaballa, A
Article. 10.1016/j.gore.2020.100594. 2020
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia, YG; (...); Gonzalez Martin A
Article. 10.1136/ijgc-2019-000256. 2019
EFFICACY OF TRABECTEDIN IN METASTATIC UTERINE LEIOMYOSARCOMA: A RETROSPECTIVE MULTICENTER STUDY OF THE SPANISH OVARIAN CANCER RESEARCH GROUP (GEICO)
Rubio, MJ; (...); Santaballa, A
Meeting Abstract. 2018
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study
Martin, M; (...); Lluch, A
Article. 10.1200/JCO.2015.61.9510. 2015
Evolution of older patients diagnosed with early breast cancer in Spain between 1998 and 2001 included in El Alamo III project
Torregrosa, MD; (...); Ruiz, A
Article. 10.1007/s12094-019-02189-6. 2019
Feasibility and Safety of a Modified Outpatient Regimen With Intravenous/Intraperitoneal Chemotherapy for Optimally Debulked Stage III Ovarian Cancer
Bruixola G; (...); Santaballa A
Article. 10.1097/IGC.0000000000000330. 2015
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "ElA Alamo III" retrospective study
Marquez-Rodas, Ivan; (...); Lopez-Tarruella, Sara
Article. 10.1371/journal.pone.0184181. 2017
GEICO1601-ROLANDO trial: A multicentric single arm phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
Fidalgo, JAP; (...); Martin, AG
Meeting Abstract. 10.1016/j.annonc.2020.08.971. 2020
GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
Perez-Fidalgo, JA; (...); Gonzalez-Martin, A
Article. 10.4155/fsoa-2018-0107. 2019
Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM).
Elez E; (...); Garrido P
Article. 10.1016/j.esmoop.2021.100048. 2021
Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).
Alejandro Perez-Fidalgo, Jose; (...); Gonzalez-Martin, Antonio
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.5549. 2021
Hypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Rodríguez-Lescure Á; (...); de la Haba-Rodriguez J
Article. 10.1007/s12094-024-03411-w. 2024
Identification of a specific epigenetic signature in patients showing secondary hypertension upon anti-VEGF treatment from the GEICAM/2011-04 (BRECOL) study
de la Haba, J; (...); Rodriguez-Lescure, A
Meeting Abstract. 10.1158/1538-7445.SABCS19-P4-10-28. 2020
Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine
Murria R; (...); Bolufer P
Article. 2015
Immunosuppressive profiles in liquid biopsy at diagnosis predict response to neoadjuvant chemotherapy in triple-negative breast cancer
Salvador-Coloma, C; (...); de Mora, JF
Article. 10.1016/j.ejca.2020.08.020. 2020
Immunosuppressive profiles in liquid biopsy predict response to neoadjuvant chemotherapy in triple negative breast cancer
Salvador-Coloma, C; (...); Santaballa, A
Meeting Abstract. 10.1158/1538-7445.SABCS18-P3-11-16. 2019
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Alamo IV registry.
Martin, Miguel; (...); Aguiar-Bujanda, David
Article. 10.1007/s10549-023-07002-1. 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Kristeleit, Rebecca; (...); Subbiah, Vivek
Article. 10.1007/s10637-023-01383-2. 2023
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study.
Longo-Munoz, Federico; (...); Subbiah, Vivek
Article. 10.1016/j.ejca.2022.06.024. 2022
Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer
Murria R; (...); Bolufer P
Article. 2015
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.
Pena-Enriquez, Regina; (...); de la Haba-Rodriguez, Juan
Article. 10.1038/s41523-025-00718-x. 2025
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
Romero, I; (...); Gonzalez-Martin, A
Article. 10.1097/CAD.0000000000000794. 2019
Multidisciplinary consensus on the criteria for fertility preservation in cancer patients.
Santaballa, A.; (...); Manau-Trullas, D.
Article. 10.1007/s12094-021-02699-2. 2022
Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
Fidalgo, JAP; (...); Gonzalez-Martin, A
Meeting Abstract. 10.1016/j.annonc.2021.08.1177. 2021
New clinical trials regulation in Spain: analysis of royal decree 1090/2015
Martin Jimenez M; (...); Segui Palmer MA
Article. 10.1007/s12094-016-1550-9. 2017
New Molecular Markers To Detect Occult Metastases in Ovarian Cortex from Breast Cancer Patients
Herraiz, Sonia; (...); Pellicer, Antonio
Article. 2013
NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A GEICO STUDY WITHIN THE SPANISH EXTENDED ACCESS PROGRAM
Cueva Banuelos, J. F.; (...); Gonzalez-Martin, A.
Meeting Abstract. 10.1136/ijgc-2021-ESGO.447. 2021
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
Perez-Fidalgo, JA; (...); Gonzalez-Martin, A
Article. 10.1016/j.esmoop.2021.100212. 2021
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.
Garcia-Donas, Jesus; (...); Grande, Enrique
Article. 10.1007/s12094-023-03085-w. 2023
Optimization of oral chemotherapy in outpatient clinics in Spain: results from a survey of the Spanish Society of Medical Oncology (SEOM)
Santaballa, A; (...); Alba, E
Article. 10.1007/s12094-018-1951-z. 2019
OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis-An exploratory joint analysis of the BRCA and non-BRCA cohorts.
Selle, Frederic; (...); Pujade-Lauraine, Eric
Meeting Abstract. 2022
Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study
Ethier, JL; (...); Martin, M
Article. 10.1016/j.ejca.2018.02.018. 2018
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Martin, Miguel; (...); Gil-Gil, Miguel
Article. 10.1016/j.ejca.2022.03.006. 2022
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
García-Donas J; (...); Navarro P
Article. 10.1016/j.ygyno.2024.10.019. 2024
Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL)
Garcia, YG; (...); Martin, AG
Meeting Abstract. 10.1200/JCO.2017.35.15_suppl.5508. 2017
Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial
Gustavo, Federico; (...); Albanell, Joan
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.1029. 2024
Plk1 expression & efficacy of palbociclib in advanced hormonal receptor-positive breast cancer patients from PEARL study (GEICAM 2012-03)
Guerrero-Zotano, A; (...); Martin, M
Meeting Abstract. 2021
Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial.
Mirza, MR; (...); Amant, F
Meeting Abstract. 10.1200/JCO.2017.35.15_suppl.TPS5613. 2017
Preclinical and clinical development of palbociclib and future perspectives
de Duenas, EM; (...); Llombart-Cussac, A
Review. 10.1007/s12094-018-1850-3. 2018
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Templeton, AJ; (...); GEICAM Study Investigators
Article. 10.1007/s12094-018-1885-5. 2018
Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2-endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study
Tibau, A; (...); Albanell, J
Meeting Abstract. 10.1016/j.annonc.2021.03.108. 2021
Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial.
Tibau, Ariadna; (...); Albanell, Joan
Article. 10.1177/17588359221148921. 2023
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Albanell, J.; (...); Rojo, F.
Article. 10.1016/j.ejca.2021.11.010. 2022
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
Harter P; (...); du Bois A
Article. 10.1056/NEJMoa2103294. 2021
Real-world clinical practice patterns and outcomes for advanced ovarian cancer in Spain (GEICO-42-R study)
Redondo, Andres; (...); Gonzalez-Martin, Antonio
Article. 10.31083/j.ejgo4206163. 2021
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
Cueva, Juan F.; (...); Gonzalez-Martin, Antonio
Article. 10.1016/j.ejca.2022.12.023. 2022
Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer
Estal, RM; (...); Gilabert, PB
Article. 10.1007/s10689-015-9864-2. 2016
Replied to "Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)".
Virizuela JA; (...); Fernández TL
Letter. 10.1007/s12094-019-02173-0. 2019
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.
Alvarez-Lopez I; (...); Santaballa Bertrán A
Review. 10.1007/s12094-019-02269-7. 2020
Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial
Perez-Fidalgo, Jose Alejandro; (...); Gonzalez-Martin, Antonio
Meeting Abstract. 2024
Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program.
Yubero, Alfonso; (...); Gonzalez-Martin, Antonio
Case Reports. 10.1016/j.gore.2023.101211. 2023
Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study
Yubero, Alfonso; (...); Gonzalez-Martin, Antonio
Article. 10.1186/s12885-022-10191-5. 2022
SEOM clinical guideline for secondary prevention (2019).
Santaballa A; (...); Bayo J
Article. 10.1007/s12094-020-02302-0. 2020
SEOM Clinical Guideline in ovarian cancer (2016)
Santaballa, A; (...); Romero, I
Article. 10.1007/s12094-016-1588-8. 2016
SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients (2016)
Munoz M; (...); Blasco A
Article. 10.1007/s12094-016-1587-9. 2016
SEOM clinical guidelines for endometrial cancer (2017)
Santaballa, A; (...); Gonzalez-Martin, A
Article. 10.1007/s12094-017-1809-9. 2018
SEOM clinical guidelines for endometrial cancer (2017) (vol 20, pg 29, 2018)
Santaballa, A; (...); Gonzalez-Martin, A
Correction. 10.1007/s12094-018-1842-3. 2018
SEOM clinical guidelines in gestational trophoblastic disease (2017)
Santaballa, A; (...); Garcia-Martinez, E
Article. 10.1007/s12094-017-1793-0. 2018
SEOM clinical guidelines on cardiovascular toxicity (2018)
Virizuela, JA; (...); Fernandez, TL
Article. 10.1007/s12094-018-02017-3. 2019
SEOM clinical guidelines to primary prevention of cancer (2018).
Bayo J; (...); Santaballa A
Article. 10.1007/s12094-018-02016-4. 2019
SEOM guidelines 2016: an update
Santaballa, A, Martin, M
Editorial Material. 10.1007/s12094-016-1592-z. 2016
SEOM-GEICO clinical guidelines on endometrial cancer (2021).
Barretina-Ginesta MP; (...); Rubio-Pérez MJ
Article. 10.1007/s12094-022-02799-7. 2022
SNPs and taxane toxicity in breast cancer patients
Bosó V; (...); Aliño SF
Article. 10.2217/PGS.14.127. 2014
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry).
Lopez-Tarruella S; (...); Carrasco E
Article. 10.1038/s41598-019-55765-9. 2019
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
Gamez-Pozo, Angelo; (...); Zamora, Pilar
Article. 10.1371/journal.pone.0109611. 2014
The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma-A Study by the Spanish Group for Ovarian Cancer Research (GEICO).
Pizarro, David; (...); Palacios, Jose
Article. 10.3390/ijms241311183. 2023
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial
Albanell, Joan; (...); Rojo Todo, Federico Gustavo
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.1028. 2024